About: Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes
Creator	Dittmer, Ulf Bayer, Wibke Groitl, Peter Johrden, Lena Lietz, Ruth Nabi, Ghulam Ontikatze, Teona Schimmer, Simone Tenbusch, Matthias Wildner, Oliver Wolf, Hans Berry, Cassandra
source	Medline; PMC
abstract	BACKGROUND: Type I interferons (IFNs) exhibit direct antiviral effects, but also distinct immunomodulatory properties. In this study, we analyzed type I IFN subtypes for their effect on prophylactic adenovirus-based anti-retroviral vaccination of mice against Friend retrovirus (FV) or HIV. RESULTS: Mice were vaccinated with adenoviral vectors encoding FV Env and Gag proteins alone or in combination with vectors encoding IFNα1, IFNα2, IFNα4, IFNα5, IFNα6, IFNα9 or IFNβ. Only the co-administration of adenoviral vectors encoding IFNα2, IFNα4, IFNα6 and IFNα9 resulted in strongly improved immune protection of vaccinated mice from subsequent FV challenge infection with high control over FV-induced splenomegaly and reduced viral loads. The level of protection correlated with augmented virus-specific CD4(+ )T cell responses and enhanced antibody titers. Similar results were obtained when mice were vaccinated against HIV with adenoviral vectors encoding HIV Env and Gag-Pol in combination with various type I IFN encoding vectors. Here mainly CD4(+ )T cell responses were enhanced by IFNα subtypes. CONCLUSIONS: Our results indicate that certain IFNα subtypes have the potential to improve the protective effect of adenovirus-based vaccines against retroviruses. This correlated with augmented virus-specific CD4(+ )T cell and antibody responses. Thus, co-expression of select type I IFNs may be a valuable tool for the development of anti-retroviral vaccines.
has issue date	2011-09-26(xsd:dateTime)
bibo:doi	10.1186/1742-4690-8-75
bibo:pmid	21943056
has license	cc-by
sha1sum (hex)	2c0c7b9bdc81461fbf533ae6b89fd78326651306
schema:url	https://doi.org/10.1186/1742-4690-8-75
resource representing a document's title	Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes
has PubMed Central identifier	PMC3193818
has PubMed identifier	21943056
schema:publication	Retrovirology
resource representing a document's body	covid:2c0c7b9bdc81461fbf533ae6b89fd78326651306#body_text
is schema:about of	named entity 'INTERFERON ' named entity 'subtypes' named entity 'PROTECTION' covid:arg/2c0c7b9bdc81461fbf533ae6b89fd78326651306 named entity 'ADMINISTRATION' named entity 'HIV' named entity 'ANTIRETROVIRAL' named entity 'SUBTYPES' named entity 'BUT' named entity 'ANALYZED' named entity 'PROPERTIES' named entity 'BASED' named entity 'EFFECT' named entity 'STUDY' named entity 'IFN' named entity 'THEIR' named entity 'RETROVIRUS' named entity 'EXHIBIT' named entity 'ANTIVIRAL' named entity 'DIRECT' named entity 'RETROVIRUS INFECTION' named entity 'FRIEND' named entity 'TYPE I' named entity 'MICE' named entity 'TYPE I INTERFERON' named entity 'ADENOVIRAL' named entity 'ENCODING' named entity 'VIRAL ANTIGENS' named entity 'TYPE I INTERFERONS' named entity 'PROPHYLACTIC' named entity 'BACKGROUND' named entity 'ADENOVIRUS' named entity 'VECTORS' named entity 'SUBTYPES' named entity 'IMPROVED' named entity 'VACCINE' named entity 'VACCINATION' named entity 'DISTINCT' named entity 'EFFECTS' named entity 'IMMUNOMODULATORY' named entity 'antiviral' named entity 'viral antigens' named entity 'Type I interferons' named entity 'mice' named entity 'adenovirus' named entity 'viral antigens' named entity 'type I interferon' named entity 'Env' named entity 'Friend virus' named entity 'detection limit' named entity 'mice' named entity 'Vaccine' named entity 'plasma' named entity 'Ad5' named entity 'type I IFNs' named entity 'adenoviral vector' named entity 'F-MuLV' named entity 'adenovirus' named entity 'viremia' named entity 'CD4 +' named entity 'epitope' named entity 'hepatitis C virus' named entity 'CD4+ T' named entity 'IFNγ' named entity 'viremia' named entity 'Gag-Pol' named entity 'murine' named entity 'antibody' named entity 'polycythemia' named entity 'cellular immune responses'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software